The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).
Dirk Schadendorf
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche
Research Funding - Merck
Keith Flaherty
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Peter Hersey
No relevant relationships to disclose
Paul D. Nathan
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Claus Garbe
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Philogen; Roche; SOBI
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Roche; SOBI
Mohammed M. Milhem
Consultant or Advisory Role - Amgen
Lev V. Demidov
No relevant relationships to disclose
Jessica Cecile Hassel
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Piotr Rutkowski
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Peter Mohr
No relevant relationships to disclose
Reinhard Dummer
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Roche
Uwe Trefzer
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Roche
James M. G. Larkin
Consultant or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer
Jochen Utikal
Honoraria - Roche
Michelle Casey
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ademi Santiago-Walker
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Laurie Jill Sherman
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Anne-Marie Martin
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Frank S. Wu
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Caroline Robert
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Roche